Investments, Funding & Disinvestment

The deal will give BioMarin access to ALE1, Alesta’s lead clinical-stage candidate for hypophosphatasia (HPP), a rare genetic bone disorder.

GM2 gangliosidoses are a group of rare inherited disorders that cause the progressive loss of nerve cells in the brain and spinal cord.

This expansion enhances its capability to produce high-potency active pharmaceutical ingredients (HPAPIs), antibody-drug conjugate (ADC) payloads, and commercial small-molecule APIs.

The Sepion 75 completes Syntegon’s established Sepion tablet coating range and is designed to support consistent scale-up, flexible batch processing and containment-focused manufacturing.

Under the agreement, LEO will pay up to US$435 million in upfront and near-term milestone payments for global rights to dersimelagon.

OmniAb was spun out of Ligand Pharmaceuticals in 2022 and has since built a broad network of pharmaceutical partnerships.

The summit will examine reforms covering healthcare financing, primary and specialised care, health commodities, digital health, the health workforce, and maternal and newborn health.

The agreement gives Zealand $50 million upfront, with another $50 million payable one year later.

The sale transfers a business that develops and supplies microbiology products used across clinical diagnostics, pharmaceutical manufacturing and food safety testing.

The licensing agreement will allow UCL to manufacture and supply generic alimatravir in African countries and other markets covered by the agreement, subject to successful clinical development and regulatory approval.